Pipex Sees Strong Data for Dry Age-Related Macular Degeneration Trial

Pipex Pharmaceuticals’ Phase II clinical trial for the treatment of dry age-related macular degeneration (AMD) using oral Zinthionein produced promising results.

The prospective, randomized, double-blind, placebo-controlled trial tested 80 patients for six months. Compared with placebo, patients treated with the drug demonstrated a significant improvement in visual acuity, contrast sensitivity and photorecovery time.

Dry AMD is the leading cause of blindness in the U.S. It affects roughly 10 million Americans and has no FDA-approved therapy, Pipex said.